KR20200042440A - 고형종양, 과다색소침착 및 통풍의 전이를 억제하기 위한 완충제의 비경구 비전신적 투여 - Google Patents

고형종양, 과다색소침착 및 통풍의 전이를 억제하기 위한 완충제의 비경구 비전신적 투여 Download PDF

Info

Publication number
KR20200042440A
KR20200042440A KR1020197033931A KR20197033931A KR20200042440A KR 20200042440 A KR20200042440 A KR 20200042440A KR 1020197033931 A KR1020197033931 A KR 1020197033931A KR 20197033931 A KR20197033931 A KR 20197033931A KR 20200042440 A KR20200042440 A KR 20200042440A
Authority
KR
South Korea
Prior art keywords
formulation
subject
buffer
skin
metastasis
Prior art date
Application number
KR1020197033931A
Other languages
English (en)
Korean (ko)
Inventor
브루스 제이. 샌드
Original Assignee
앰퍼샌드 바이오파마슈티컬스, 엘엘씨
브루스 제이. 샌드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앰퍼샌드 바이오파마슈티컬스, 엘엘씨, 브루스 제이. 샌드 filed Critical 앰퍼샌드 바이오파마슈티컬스, 엘엘씨
Publication of KR20200042440A publication Critical patent/KR20200042440A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197033931A 2017-04-17 2018-04-17 고형종양, 과다색소침착 및 통풍의 전이를 억제하기 위한 완충제의 비경구 비전신적 투여 KR20200042440A (ko)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201762602227P 2017-04-17 2017-04-17
US62/602,227 2017-04-17
US201762602358P 2017-04-20 2017-04-20
US201762602359P 2017-04-20 2017-04-20
US62/602,359 2017-04-20
US62/602,358 2017-04-20
US201762559360P 2017-09-15 2017-09-15
US62/559,360 2017-09-15
US201762559947P 2017-09-18 2017-09-18
US62/559,947 2017-09-18
US201762562725P 2017-09-25 2017-09-25
US62/562,725 2017-09-25
US201762609982P 2017-12-22 2017-12-22
US62/609,982 2017-12-22
US201862639904P 2018-03-07 2018-03-07
US62/639,904 2018-03-07
PCT/US2018/028017 WO2018195111A1 (en) 2017-04-17 2018-04-17 Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout

Publications (1)

Publication Number Publication Date
KR20200042440A true KR20200042440A (ko) 2020-04-23

Family

ID=63856054

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033931A KR20200042440A (ko) 2017-04-17 2018-04-17 고형종양, 과다색소침착 및 통풍의 전이를 억제하기 위한 완충제의 비경구 비전신적 투여

Country Status (7)

Country Link
EP (1) EP3612274A4 (ja)
JP (1) JP2020516690A (ja)
KR (1) KR20200042440A (ja)
CN (1) CN111093774A (ja)
AU (3) AU2018255294B2 (ja)
MX (1) MX2019012385A (ja)
WO (1) WO2018195111A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4349414A2 (en) 2014-12-23 2024-04-10 Dyve Biosciences, Inc. Methods and formulations for transdermal administration
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
US20190201327A1 (en) * 2017-09-25 2019-07-04 Ampersand Biopharmaceuticals, Inc. Topical applications of withaferin a
WO2020086766A1 (en) * 2018-10-23 2020-04-30 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of dermal contouring agents
EP3906059A4 (en) * 2018-11-02 2022-06-22 Ampersand Biopharmaceuticals, Inc. MANAGING THE RISK OF CATION OVERLOAD AND ELECTROLYTE BALANCE WITH TOPICALLY APPLIED BUFFER
US20210059955A1 (en) * 2019-08-26 2021-03-04 RL Patents, LLC Systems and methods for decrystallization of uric acid
US20230330041A1 (en) * 2020-08-27 2023-10-19 Beijing Changsheng Pharmaceutical Technology Co., Ltd. Application of tris (hydroxymethyl) aminomethane pharmaceutically acceptable salt to drugs for treating hyperuricemia
CN113181149A (zh) * 2021-06-11 2021-07-30 北京畅盛医药科技有限公司 一种治疗痛风性关节炎的皮肤外用药物制剂
CN116539880B (zh) * 2022-12-05 2023-12-08 四川大学华西医院 检测代谢物和/或组织蛋白的试剂在制备痛风性关节炎筛查试剂盒中的用途
CN116284814A (zh) * 2023-01-17 2023-06-23 杭州三式化妆品有限公司 超分子传明酸甘醇酸离子盐及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176918A (en) * 1990-12-20 1993-01-05 Jones Jeffry L Topical medicament
ATE212549T1 (de) * 1996-04-04 2002-02-15 Hoffmann La Roche Verwendung von tetrahydrobetacarbolin-derivaten zur vorbeugung der metastasenbildung
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20030228374A1 (en) * 2002-06-07 2003-12-11 Pesacreta Thomas C. Topical treatment for skin irritation
AU2002950308A0 (en) * 2002-07-23 2002-09-12 Phoenix Eagle Company Pty Ltd Topically applied composition
CA2645073A1 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US20110230551A1 (en) * 2008-09-15 2011-09-22 Leslie Gunatilaka Withaferin a analogs and uses thereof
CN101897784A (zh) * 2009-05-27 2010-12-01 北京因科瑞斯医药科技有限公司 一种用于痛风的中药组合物及其制备方法
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
WO2011066379A2 (en) * 2009-11-24 2011-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION
WO2012064429A2 (en) * 2010-11-09 2012-05-18 The Regents Of The University Of California Skin permeating and cell entering (space) peptides and methods of use thereof
RU2593848C2 (ru) * 2011-03-29 2016-08-10 Неокемир Инк. Противоопухолевое средство, содержащее диоксид углерода в качестве активного ингредиента
US9266815B2 (en) * 2012-03-28 2016-02-23 University Of Central Florida Research Foundation, Inc. Anti-metastatic agents predicated upon polyamine macrocyclic conjugates
EP4349414A2 (en) * 2014-12-23 2024-04-10 Dyve Biosciences, Inc. Methods and formulations for transdermal administration
CN106236937A (zh) * 2016-08-31 2016-12-21 腾冲恒益东山休闲度假有限责任公司 能缓解痛风性关节炎的泡浴液

Also Published As

Publication number Publication date
MX2019012385A (es) 2022-03-15
JP2020516690A (ja) 2020-06-11
AU2018255294A1 (en) 2019-12-05
AU2023254920A1 (en) 2023-11-16
EP3612274A4 (en) 2021-05-26
AU2022241559A1 (en) 2022-10-27
CN111093774A (zh) 2020-05-01
AU2022241559B2 (en) 2023-07-27
AU2018255294B2 (en) 2022-07-28
EP3612274A1 (en) 2020-02-26
WO2018195111A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
KR20200042440A (ko) 고형종양, 과다색소침착 및 통풍의 전이를 억제하기 위한 완충제의 비경구 비전신적 투여
US11389472B2 (en) Method of administration and treatment
CN115634282A (zh) 贻贝粘蛋白产品治疗和预防黑色素相关疾病中的应用
ES2932550T3 (es) Composiciones estimulantes de células madre y métodos para tratar el melasma
KR101599447B1 (ko) 조성물 및 항문 치열 치료에서의 그 용도
KR101623375B1 (ko) 키토산 및 디카르복실산을 포함하는 주사 질환의 치료용 조성물
US20150071880A1 (en) Treatment of epithelial layer lesions
JP2001322990A (ja) 活性酸素消去剤及びそれを含有する活性酸素消去用の組成物
JP6656890B2 (ja) フィラグリン産生促進剤
CN116350746B (zh) 沙丁鱼肽组合物在治疗过敏性鼻炎的药物中的应用
KR102572861B1 (ko) 지방분해 효과가 개선된 데옥시콜산 조성물 및 이의 제조 방법
US11773081B2 (en) Pharmaceutical composition for preventing or treating wound, comprising indirubin derivative as active ingredient
KR101754556B1 (ko) 수베르산 또는 이의 염을 유효성분으로 함유하는 피부보습 개선 또는 피부탄력 증진 효과를 갖는 조성물
JP2004018508A (ja) ケラチナーゼ活性阻害剤、及び皮膚外用剤、皮膚洗浄剤又は足浴剤
EP3397241A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E601 Decision to refuse application